StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) to Make Repatha Available Exclusively at Lower List Price Option
October 24, 2019 9:01 AM
Amgen (NASDAQ: AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Management Comments
Next Articles
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
October 24, 2019 9:00 AM